Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Buprenorphine Pharmacology Related to Addiction Treatment - 18

10:33 EDT 19th April 2014 | BioPortfolio

Summary

The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.

Study Design

Primary Purpose: Treatment

Conditions

Opioid-Related Disorders

Intervention

Buprenorphine/naloxone

Location

Treatment Research Center
Burlington
Vermont
United States
05401

Status

Completed

Source

National Institute on Drug Abuse (NIDA)

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

Disorders related or resulting from abuse or mis-use of opioids.

An opioid antagonist with properties similar to those of NALOXONE; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia, 30th ed, p683)

Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.

A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.

Clinical Trials [628 Associated Clinical Trials listed on BioPortfolio]

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The...

Abuse Potential of Buprenorphine/Naloxone

Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. Th...

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

Buprenorphine is a medication used to treat opioid addiction, but individuals who use this drug are at risk of abusing it. A buprenorphine and naloxone combination may reduce the likelihoo...

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxon...

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or bupr...

PubMed Articles [10170 Associated PubMed Articles listed on BioPortfolio]

Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.

To review current evidence on buprenorphine-naloxone (bup/nx) for the treatment of opioid-use disorders, with a focus on strategies for clinical management and office-based patient care.

Long-term opioids and naloxone administration in a district general hospital.

Respiratory depression is a known side effect of opioid medications. Naloxone is an opioid antagonist used in the reversal of opioid overdose. The use of naloxone in patients on long-term opioids can...

Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.

To examine awareness of, experience with, and attitudes toward buprenorphine, to begin to understand why opioid users may not access buprenorphine treatment. Factors associated with attitudes toward b...

Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.

Naloxone for Opioid Overdose Prevention: Pharmacists' Role in Community-Based Practice Settings.

Deaths related to opioid overdose have increased in the past decade. Community-based pharmacy practitioners have worked toward overcoming logistic and cultural barriers to make naloxone distribution f...

More From BioPortfolio on "Buprenorphine Pharmacology Related to Addiction Treatment - 18"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Trial